Focused on the patient - Baylor Health Care System

More documents

Recommendations

Info

38<strong>Focused</strong> on innovationOncology Publications in 20071. Batts ED, Maisel C, Kane D, Liu L, Fu P, O’Brien T, Remick S, Bahlis N,Gerson SL. O6-benzylguanine and BCNU in multiple myeloma: a phase IItrial. Cancer Chemother Pharmacol 2007;60(3):415–421.2. Blum JL, Dees EC, Vukelja SJ, Amare M, Gill DP, McMahon RT, IlegboduD, Asmar L, O’Shaughnessy JA. Phase II trial of capecitabine and weeklypaclitaxel in patients with metastatic breast cancer previously treatedwith every-3-week taxane therapy. Clin Breast Cancer 2007;7(6):465–470.3. Boland CR. Clinical uses of microsatellite instability testing in colorectalcancer: an ongoing challenge. J Clin Oncol 2007;25(7):754–756.4. Boland CR, Koi M, Chang DK, Carethers JM. The biochemical basis ofmicrosatellite instability and abnormal immunohistochemistry and clinicalbehavior in Lynch syndrome: from bench to bedside. Fam Cancer 2007Jul 17 [Epub ahead of print].5. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE,Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L,Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D,Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, CastiglioneM, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, CarpentieriM, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup ExemestaneStudy. Survival and safety of exemestane versus tamoxifen after2-3 years’ tamoxifen treatment: a randomised controlled trial. Lancet2007;369(9561):559–570.6. Dao TN, Lamont JP, Knox SM. Clinical utility of breast magnetic resonanceimaging in patients presenting with primary breast cancer. Proc(Bayl Univ Med Cent) 2007;20(3):227–230.7. Eager R, Harle L, Nemunaitis JJ. Lung cancer vaccines. Curr Gene Ther2007;7(6):469–484.8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, NegrierS, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, HutsonTE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, BukowskiRM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cellcarcinoma. N Engl J Med 2007;356(2):125–134.9. Ewer MS, O’Shaughnessy JA. Cardiac toxicity of trastuzumab-relatedregimens in HER2-overexpressing breast cancer. Clin Breast Cancer2007;7(8):600–607.10. Fini L, Hotchkiss E, Fogliano V, Graziani G, Romano M, De Vol EB, QinH, Selgrad M, Boland CR, Ricciardiello L. Chemopreventive propertiesof pinoresinol-rich olive oil involve a selective activation of the ATM-p53cascade in colon cancer cell lines. Carcinogenesis 2007 Nov 13 [Epubahead of print].11. Fini L, Selgrad M, Fogliano V, Graziani G, Romano M, Hotchkiss E,Daoud YA, De Vol EB, Boland CR, Ricciardiello L. Annurca applepolyphenols have potent demethylating activity and can reactivatesilenced tumor suppressor genes in colorectal cancer cells. J Nutr2007;137(12):2622–2628.12. Fisher PB, Sarkar D, Lebedeva IV, Emdad L, Gupta P, Sauane M, SuZZ, Grant S, Dent P, Curiel DT, Senzer N, Nemunaitis J. Melanomadifferentiation associated gene-7/interleukin-24 (mda-7/IL-24): novelgene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol2007;224(3):300–307.13. George S, Hutson TE, Mekhail T, Wood L, Finke J, Elson P, Dreicer R,Bukowski RM. Phase I trial of PEG-interferon and recombinant IL-2 inpatients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol2007 [Epub ahead of print].14. Georges GE, Maris MB, Maloney DG, Sandmaier BM, Sorror ML,Shizuru JA, Lange T, Agura ED, Bruno B, McSweeney PA, PulsipherMA, Chauncey TR, Mielcarek M, Storer BE, Storb R. Nonmyeloablativeunrelated donor hematopoietic cell transplantation to treat patients withpoor-risk, relapsed, or refractory multiple myeloma. Biol Blood MarrowTransplant 2007;13(4):423–432.15. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D,Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, Boland CR. TheCpG island methylator phenotype and chromosomal instability areinversely correlated in sporadic colorectal cancer. Gastroenterology2007;132(1):127–138.16. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB 3rd, BlankeCD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK,Becerra CH, Wickham R, Armstrong D, Viele C. The continuum of care: aparadigm for the management of metastatic colorectal cancer. Oncologist2007;12(1):38–50.17. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, ValeroV, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, HessKR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF. Determinationof oestrogen-receptor status and ERBB2 status of breast carcinoma: agene-expression profiling study. Lancet Oncol 2007;8(3):203–211.18. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube7 S, SomerfieldMR, Hayes DF, Bast RC Jr; American Society of Clinical Oncology. AmericanSociety of Clinical Oncology 2007 update of recommendations forthe use of tumor markers in breast cancer. J Clin Oncol 2007;25(33):5287–5312.19. Hutson TE. Safety and tolerability of sorafenib in clear-cell renal cellcarcinoma: a phase III overview. Expert Rev Anticancer Ther2007;7(9):1193–1202.20. Hutson TE. Targeted therapy for renal cell carcinoma: a new treatmentparadigm. Proc (Bayl Univ Med Cent) 2007;20(3):244–248.21. Hutson TE, Figlin RA. Evolving role of novel targeted agents in renal cellcarcinoma. Oncology (Williston Park) 2007;21(10):1175–1180.22. Hutson TE, Figlin RA. Renal cell cancer. Cancer J 2007;13(5):282–286.23. Jay C, Nemunaitis J, Chen P, Fulgham P, Tong AW. miRNA profiling fordiagnosis and prognosis of human cancer. DNA Cell Biol 2007;26(5):293–300.24. Jones SE, Cantrell J, Vukelja S, Pippen J, O’Shaughnessy J, Blum JL,Brooks R, Hartung NL, Negron AG, Richards DA, Rivera R, Holmes FA,Chittoor S, Whittaker TL, Bordelon JH, Ketchel SJ, Davis JC, IlegboduD, Kochis J, Asmar L. Comparison of menopausal symptoms during thefirst year of adjuvant therapy with either exemestane or tamoxifen in earlybreast cancer: report of a Tamoxifen Exemestane Adjuvant Multicentertrial substudy. J Clin Oncol 2007;25(30):4765–4771.25. Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG,Niederwieser D, Chauncey TR, Forman SJ, Agura E, Leis JF, Bruno B,Langston A, Pulsipher MA, McSweeney PA, Wade JC, Epner E, Bo PetersenF, Bethge WA, Maloney DG, Storb R. Relapse risk in patients withmalignant diseases given allogeneic hematopoietic cell transplantationafter nonmyeloablative conditioning. Blood 2007;110(7):2744–2748.26. Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS,Mok SC. Effect of a c-Met-specific, ATP-competitive small-moleculeinhibitor SU11274 on human ovarian carcinoma cell growth, motility, andinvasion. Int J Gynecol Cancer 2007 Nov 16 [Epub ahead of print].27. Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D,Conrad C, Fink KL, Robins HI, Mehta M, Deangelis L, Raizer J, Hess K,Lamborn KR, Dancey J, Prados MD; for the North American Brain TumorConsortium and the National Cancer Institute. Pharmacokinetic and tumordistribution characteristics of temsirolimus in patients with recurrent malignantglioma. Clin Cancer Res 2007;13(24):7401–7406.28. Kuhn JA, Nochumson J. Operative probe scintimetry with indium andtechnetium for colorectal cancer. J Surg Oncol 2007;96(4):290–296.29. Lebedeva IV, Emdad L, Su ZZ, Gupta P, Sauane M, Sarkar D, Staudt MR,Liu SJ, Taher MM, Xiao R, Barral P, Lee SG, Wang D, Vozhilla N, ParkES, Chatman L, Boukerche H, Ramesh R, Inoue S, Chada S, Li R, DePass AL, Mahasreshti PJ, Dmitriev IP, Curiel DT, Yacoub A, Grant S, DentP, Senzer N, Nemunaitis JJ, Fisher PB. mda-7/IL-24, novel anticancercytokine: focus on bystander antitumor, radiosensitization and antiangiogenicproperties and overview of the phase I clinical experience. Int JOncol 2007;31(5):985–1007.
<strong>Focused</strong> on innovation 3930. Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL,Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, Deangelis LM,Robins IH, Aldape KD, Yung WK. Phase I study of temozolomide andirinotecan for recurrent malignant gliomas in patients receiving enzymeinducingantiepileptic drugs: a North American Brain Tumor Consortiumstudy. Clin Cancer Res 2007;13(23):7133–7138.31. Lynch HT, Boland CR, Rodriguez-Bigas MA, Amos C, Lynch JF, LynchPM. Who should be sent for genetic testing in hereditary colorectal cancersyndromes? J Clin Oncol 2007;25(23):3534–3542.32. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, RixeO, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, BaumCM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cellcarcinoma. N Engl J Med 2007;356(2):115–124.33. Nemunaitis JJ. Molecular mapping for personalized cancer therapeutics.DMJ 2007;93(10):346–349.34. Nemunaitis J, Nemunaitis J. A review of vaccine clinical trials for nonsmallcell lung cancer. Expert Opin Biol Ther 2007;7(1):89–102.35. Nemunaitis J, Senzer N, Khalil I, Shen Y, Kumar P, Tong A, Kuhn J, LamontJ, Nemunaitis M, Rao D, Zhang YA, Zhou Y, Vorhies J, Maples P, HillC, Shanahan D. Proof concept for clinical justification of network mappingfor personalized cancer therapeutics. Cancer Gene Ther 2007;14(8):686–695.36. Nemunaitis J, Senzer N, Sarmiento S, Zhang YA, Arzaga R, Sands B,Maples P, Tong AW. A phase I trial of intravenous infusion of ONYX-015and enbrel in solid tumor patients. Cancer Gene Ther 2007;14(11):885–893.37. Nemunaitis J, Vorhies JS, Pappen B, Senzer N. 10-year follow-up ofgene-modified adenoviral-based therapy in 146 non-small-cell lung cancerpatients. Cancer Gene Ther 2007;14(8):762–763.38. Nishida N, Nagasaka T, Kashiwagi K, Boland CR, Goel A. High copy amplificationof the Aurora-A gene is associated with chromosomal instabilityphenotype in human colorectal cancers. Cancer Biol Ther 2007;6(4):525–533.39. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. Aberrantmethylation of multiple tumor suppressor genes in aging liver, chronichepatitis, and hepatocellular carcinoma. Hepatology 2007 Dec 26 [Epubahead of print].40. Nishida N, Nishimura T, Nagasaka T, Ikai I, Goel A, Boland CR. Extensivemethylation is associated with beta-catenin mutations in hepatocellularcarcinoma: evidence for two distinct pathways of human hepatocarcinogenesis.Cancer Res 2007;67(10):4586–4594.41. Ogino S, Goel A. Molecular classification and correlates in colorectalcancer. J Mol Diagn 2007 [Epub ahead of print].42. O’Shaughnessy J. A decade of letrozole: FACE. Breast Cancer Res Treat2007;105(Suppl 1):67–74.43. Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S,Robins HI, Dancey J, Kuhn J. Phase-1 trial of gefitinib and temozolomidein patients with malignant glioma: a North American brain tumor consortiumstudy. Cancer Chemother Pharmacol 2007 Aug 11 [Epub ahead ofprint].44. Ravandi F, Burnett AK, Agura ED, Kantarjian HM. Progress in the treatmentof acute myeloid leukemia. Cancer 2007;110(9):1900–1910.45. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT, WadeJC, Chauncey T, Forman SJ, Lange T, Shizuru J, Langston A, PulsipherMA, Sandmaier BM, Storb R, Maloney DG. Nonmyeloablative allogeneichematopoietic cell transplantation in relapsed, refractory, and transformedindolent non-Hodgkin’s lymphoma. J Clin Oncol 2007 Dec 3 [Epub aheadof print].46. Roukounakis N, Manolakopoulos S, Tzourmakliotis D, Bethanis S,McCarty TM, Kuhn J. Biliary tract malignancy and abnormal pancreaticobiliaryjunction in a Western population. J Gastroenterol Hepatol2007;22(11):1949–1952.47. Segota E, Mekhail T, Olencki T, Hutson TE, Dreicer R, Wacker B, OsterwalderB, Elson P, Zhou M, Bukowski RM. Phase II trial of capecitabineand rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma,limited efficacy, and moderate toxicity. Urol Oncol 2007;25(1):46–52.48. Senzer N, Nemunaitis J, Nemunaitis M, Lamont J, Gore M, Gabra H, EelesR, Sodha N, Lynch FJ, Zumstein LA, Menander KB, Sobol RE, ChadaS. p53 therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Ther2007;6(5):1478–1482.49. Shin SK, Nagasaka T, Jung BH, Matsubara N, Kim WH, CarethersJM, Boland CR, Goel A. Epigenetic and genetic alterations in Netrin-1receptors UNC5C and DCC in human colon cancer. Gastroenterology2007;133(6):1849–1857.50. Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, NelsonWG, Ando D, Howard C, Borellini F, Nguyen M, Hege K, Simons JW.Granulocyte macrophage colony-stimulating factor–secreting allogeneiccellular immunotherapy for hormone-refractory prostate cancer. ClinCancer Res 2007;13(13):3883–3891.51. Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE, GalskyMD, Berry WR, Kadmon D. Neoadjuvant therapy followed by prostatectomyfor clinically localized prostate cancer. Cancer 2007;110(12):2628–2639.52. Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinaseinhibitor. Curr Oncol Rep 2007;9(2):115–119.53. Sonpavde G, Hutson TE. Recent advances in the therapy of renal cancer.Expert Opin Biol Ther 2007;7(2):233–242.54. Sonpavde G, Hutson TE, Roth BJ. Management of recurrent testiculargerm cell tumors. Oncologist 2007;12(1):51–61.55. Sonpavde G, Ross R, Powles T, Sweeney CJ, Hahn N, Hutson TE, GalskyMD, Lerner SP, Sternberg CN. Novel agents for muscle-invasive andadvanced urothelial cancer. BJU Int 2007 [Epub ahead of print].56. Stone MJ. Evarts A. Graham. In Bynum WF, Bynum H, eds. Dictionary ofMedical Biography, Vol. 2. Westport, CT: Greenwood Press, 2007:573.57. Stone MJ. James Ewing. In Bynum WF, Bynum H, eds. Dictionary ofMedical Biography, Vol. 2. Westport, CT: Greenwood Press, 2007:467—468.58. Stone MJ. Maxwell Myer Wintrope. In Bynum WF, Bynum H, eds.Dictionary of Medical Biography, Vol. 5. Westport, CT: Greenwood Press,2007:1314—1315.59. Stone MJ. Sidney Farber. In Bynum WF, Bynum H, eds. Dictionary ofMedical Biography, Vol. 2. Westport, CT: Greenwood Press, 2007:475—476.60. Stone MJ. Thomas Hodgkin. In Bynum WF, Bynum H, eds. Dictionary ofMedical Biography, Vol. 2. Westport, CT: Greenwood Press, 2007:655—657.61. Stone MJ. William Bradley Coley. In Bynum WF, Bynum H, eds. Dictionaryof Medical Biography, Vol. 2. Westport, CT: Greenwood Press,2007:361.62. Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, WeinsteinMC. Cost-effectiveness of switching to exemestane after 2 to 3 yearsof therapy with tamoxifen in postmenopausal women with early-stagebreast cancer. Value Health 2007;10(5):367–376.63. Vorhies JS, Nemunaitis J. Nonviral delivery vehicles for use in shorthairpin RNA-based cancer therapies. Expert Rev Anticancer Ther2007;7(3):373–382.64. Vukelja SJ, Anthony SP, Arseneau JC, Berman BS, Cunningham CC,Nemunaitis JJ, Samlowski WE, Fowers KD. Phase 1 study of escalatingdoseOncoGel (ReGel/paclitaxel) depot injection, a controlled-releaseformulation of paclitaxel, for local management of superficial solid tumorlesions. Anticancer Drugs 2007;18(3):283–289.65. Zinner RG, Nemunaitis J, Eiseman I, Shin HJ, Olson SC, Christensen J,Huang X, Lenehan PF, Donato NJ, Shin DM. Phase I clinical and pharmacodynamicevaluation of oral CI-1033 in patients with refractory cancer.Clin Cancer Res 2007;13(10):3006–3014.
Page 1 and 2: Baylor Charles A. SammonsCancer Cen
Page 3: FROM THE DIRECTOR 1The Baylor Sammo
Page 6 and 7: 4Focused on youThi
Page 8 and 9: 6Focused on youAt
Page 10: 8Focused on youUni
Page 14 and 15: 12Focused on speci
Page 23 and 24: Focused on quality
Page 31: Focused on quality
Page 34 and 35: 32Focused on colla
Page 37 and 38: Focused on innovat
Page 39: Focused on innovat
Page 43 and 44: Baylor Sammons Cancer Center Teleph

Focused on the patient - Baylor Health Care System

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?